Fairvalue-Calculator Fairvalue-Calculator
EN DE

Jiangsu Aidea Pharmaceutical Group (688488) Fair Value & Analysis

Healthcare · CN · Market cap 5.3B CNY

Price¥11.98
Fair Value¥3.28
Upside-72.6%
Quality87/100
Evidence: Medium Range ¥2.42 – ¥4.14

Fair value as of: Jun 24, 2026

Analysis

Jiangsu Aidea Pharmaceutical Group (688488) currently trades at ¥11.98, while our model-based Fair Value estimate is ¥3.28 — implying the stock looks roughly 72.6% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products. The company was formerly known as Jiangsu Aidea Pharmaceutical Co., Ltd. and changed its name to Jiangsu Aidea Pharmaceutical Group Co., Ltd. in July 2025. Jiangsu Aidea Pharmaceutical Group Co., Ltd. was founded in 2009 and is headquartered in Yangzhou, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Jiangsu Aidea Pharmaceutical Group (688488) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥3.28 versus a price of ¥11.98 — about −73% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 688488?
Our 21-model fair value for Jiangsu Aidea Pharmaceutical Group is ¥3.28 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥11.98.
What is the quality score of 688488?
Jiangsu Aidea Pharmaceutical Group has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.